These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18007544)

  • 1. Formoterol (Perforomist) for COPD.
    Med Lett Drugs Ther; 2007 Nov; 49(1274):94-5. PubMed ID: 18007544
    [No Abstract]   [Full Text] [Related]  

  • 2. Formoterol dry-powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease.
    Prenner BM
    Expert Opin Pharmacother; 2007 Dec; 8(17):3069-84. PubMed ID: 18001266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arformoterol (Brovana) for COPD.
    Med Lett Drugs Ther; 2007 Jul; 49(1264):53-5. PubMed ID: 17595597
    [No Abstract]   [Full Text] [Related]  

  • 4. Arformoterol tartrate in the treatment of COPD.
    Cazzola M; Hanania NA; Matera MG
    Expert Rev Respir Med; 2010 Apr; 4(2):155-62. PubMed ID: 20406080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
    Cave AC; Hurst MM
    Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease.
    Berger WE; Nadel JA
    Respir Med; 2008 Feb; 102(2):173-88. PubMed ID: 18023995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiotropium (Spiriva) for COPD.
    Med Lett Drugs Ther; 2004 May; 46(1183):41-2. PubMed ID: 15159658
    [No Abstract]   [Full Text] [Related]  

  • 10. Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature.
    Friedman M; Della Cioppa G; Kottakis J
    Pharmacotherapy; 2002 Sep; 22(9):1129-39. PubMed ID: 12222549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
    Molimard M; Till D; Stenglein S; Singh D; Krummen M
    Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
    Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R
    Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
    Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
    Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of inhaled formoterol in the treatment of asthma.
    Berger WE
    Ann Allergy Asthma Immunol; 2006 Jul; 97(1):24-33. PubMed ID: 16892777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD.
    Cazzola M; Noschese P; De Michele F; D'Amato G; Matera MG
    Respir Med; 2006 Feb; 100(2):212-7. PubMed ID: 15936184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with maintenance budesonide and formoterol in COPD.
    Medford AR
    Eur Respir J; 2004 Dec; 24(6):1070; author reply 1070-1. PubMed ID: 15572556
    [No Abstract]   [Full Text] [Related]  

  • 17. Formoterol in the management of chronic obstructive pulmonary disease.
    Steiropoulos P; Tzouvelekis A; Bouros D
    Int J Chron Obstruct Pulmon Dis; 2008; 3(2):205-15. PubMed ID: 18686730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.
    Derom E; Strandgården K; Schelfhout V; Borgström L; Pauwels R
    Respir Med; 2007 Sep; 101(9):1931-41. PubMed ID: 17544264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The beta2-adrenergic receptor agonists in the treatment of chronic obstructive pulmonary disease].
    Chorostowska-Wynimko J
    Przegl Lek; 2005; 62(7):724-8. PubMed ID: 16463710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [COPD--comparison between once- and twice daily administration of formoterol]].
    Schneider S
    Pneumologie; 2007 Dec; 61(12):752. PubMed ID: 18275012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.